BOTHELL, Wash. (AP) ¿ Development-stage biotechnology company Seattle Genetics Inc. said Thursday its third-quarter loss narrowed on higher revenue from partnerships.

The company lost $19.8 million, or 21 cents per share, compared with a loss of $21.8 million, or 27 cents per share, during the same period a year prior. Revenue rose 44 percent to $11.6 million from $8.1 million.

Analysts polled by Thomson Reuters expected a loss of 25 cents per share on revenue of $9.4 million.

The company's key partnership is with Genentech Inc., now part of Roche. The companies are developing potential cancer treatments.

Shares of Seattle Genetics rose 12 cents to close at $9.85.

Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

More from Technology

Will Porsche's Electric Car Push Take Down Tesla?

Will Porsche's Electric Car Push Take Down Tesla?

Intel CEO Brian Krzanich Steps Down: Here Are Some of His Biggest Moves

Intel CEO Brian Krzanich Steps Down: Here Are Some of His Biggest Moves

Intel CEO Out After Past Relationship With Staffer - Why Stock Is Now in Play

Intel CEO Out After Past Relationship With Staffer - Why Stock Is Now in Play

Jim Cramer on Micron: Listen to the Conference Call

Jim Cramer on Micron: Listen to the Conference Call

Jim Cramer: Disney Has Much More Staying Power Worldwide Than Netflix

Jim Cramer: Disney Has Much More Staying Power Worldwide Than Netflix